Literature DB >> 9828902

Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.

S Tsagarakis1, C Roboti, P Kokkoris, V Vasiliou, C Alevizaki, N Thalassinos.   

Abstract

OBJECTIVE: It has recently been suggested that autonomous cortisol production may lead to subclinical glucocorticoid excess in a substantial number of patients with incidentally discovered adrenocortical adenomas. Following a standard low-dose dexamethasone suppression test (LDDST) cortisol concentrations are frequently incompletely suppressed in patients with adrenal incidentalomas, due to an ACTH-independent secretion of cortisol by the adrenal mass. Thus, post LDDST cortisol concentrations may provide a measure of the degree of autonomous glucocorticoid secretion, but hormonal alterations in relation to post-LDDST cortisol concentrations have not been thoroughly investigated. PATIENTS AND MEASUREMENTS: 61 patients with radiological features highly suggestive of adrenal adenomas were studied. These included 43 women, 18 men; mean age 59 +/- 1.4, range: 25-76 years; BMI 30.9 +/- 0.8 kg/m2 and waist:hip ratio 0.90 +/- 0.016. All subjects underwent a standard LDDST, as follows: after a 48-hr stabilisation period, 24-hr urine collections for basal urinary free cortisol (UFC) were performed. Basal serum cortisol and plasma ACTH were measured at 8 AM and at midnight the following day, and subjects started dexamethasone 0.5 mg 6 hourly for 2 days. Post-dexamethasone cortisol and ACTH levels were measured at 8 AM, 6-hrs after the last dose of dexamethasone. Blood samples for dehydroepiandrosterone sulphate (DHEAS) and serum lipids were obtained on the morning preceding dexamethasone administration.
RESULTS: Post-LDDST cortisol concentrations correlated positively with the size of the adenoma (r = +0.527, P < 0.001). There was a negative rank correlation of post-LDDST cortisol concentrations and basal ACTH levels at 0900 h (rs = -0.426, P < 0.001) and DHEAS (rs = -0.380, P = 0.006). Moreover, there was a good rank correlation between DHEAS and basal ACTH levels (rs = +0.456, P < 0.001). A positive rank correlation was observed between post-LDDST cortisol concentrations and midnight cortisol concentrations (rs = +0.317, P = 0.020). As recent studies have suggested that post-LDDST cortisol levels higher than 70 nmol/l may indicate significant hypercortisolism comparisons were also performed between patients divided according to post-LDDST cortisol values into 3 groups: Group A, > 70 nmol/l (19 pts); Group B, 30-70 nmol/l (27 pts); Group C, < 30 nmol/l (15 pts). Although there was no difference in basal cortisol and UFC values between these groups, ACTH and DHEAS levels were significantly lower, and midnight cortisol significantly higher in group A compared to group C patients (P = 0.030, P = 0.017 and P = 0.001 respectively). Cholesterol and triglyceride levels were slightly albeit significantly higher in group A compared to group C patients (P < 0.05).
CONCLUSIONS: It is concluded that higher post-low dose dexamethasone cortisol concentrations are associated with lower ACTH and dehydroepiandrosterone sulphate, higher midnight cortisol concentrations and larger adenomas. These findings are consistent with the hypothesis that post-low dose dexamethasone cortisol concentrations represent a useful index in assessing subtle glucocorticoid autonomy in patients with adrenal adenomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828902     DOI: 10.1046/j.1365-2265.1998.00509.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

Review 1.  Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications.

Authors:  S Tsagarakis; D Vassiliadi; N Thalassinos
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Subclinical hypercortisolism: debatable or visible on the lightbox?

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

3.  Clinical and biochemical impact of BCL1 polymorphic genotype of the glucocorticoid receptor gene in patients with adrenal incidentalomas.

Authors:  M Tzanela; E Mantzou; K Saltiki; M Tampourlou; N Kalogeris; D Hadjidakis; S Tsagarakis; M Alevizaki
Journal:  J Endocrinol Invest       Date:  2011-07-05       Impact factor: 4.256

4.  DHEAS for the prediction of subclinical Cushing's syndrome: perplexing or advantageous?

Authors:  Serkan Yener; Hamiyet Yilmaz; Tevfik Demir; Mustafa Secil; Abdurrahman Comlekci
Journal:  Endocrine       Date:  2014-08-22       Impact factor: 3.633

Review 5.  Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Nat Rev Endocrinol       Date:  2011-06-28       Impact factor: 43.330

Review 6.  Subclinical Cushing's syndrome.

Authors:  Massimo Terzolo; Giuseppe Reimondo; Silvia Bovio; Alberto Angeli
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

7.  Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas.

Authors:  Dimitra Argyro Vassiliadi; Georgia Ntali; Theodora Stratigou; Mersilena Adali; Stylianos Tsagarakis
Journal:  Endocrine       Date:  2011-05-20       Impact factor: 3.633

Review 8.  The adrenal incidentaloma: disease of modern technology and public health problem.

Authors:  D C Aron
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

9.  [Adrenal incidentalomas].

Authors:  P Langer; J Waldmann; M Rothmund
Journal:  Chirurg       Date:  2007-08       Impact factor: 0.955

10.  The aldosterone to renin ratio in the evaluation of patients with incidentally detected adrenal masses.

Authors:  M Tzanela; G Effraimidis; G Effremidis; D Vassiliadi; A Szabo; N Gavalas; A Valatsou; E Botoula; N C Thalassinos
Journal:  Endocrine       Date:  2007-11-27       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.